Table 3 Patient outcomes and anti-platelet/coagulant therapy for secondary prevention at discharge in platelet quartiles
From: Baseline platelet count may predict short-term functional outcome of cerebral infarction
Platelet quartiles platelet count range (× 109/L) | Q1 (96) 138 ± 31 19–173 | Q2 (96) 190 ± 9 174–204 | Q3 (96) 223 ± 11 205–242 | Q4 (97) 307 ± 117 243–1327 | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | ||
mRS3-6 | 22 | 22.9 | 10 | 10.4 | 10 | 10.4 | 25 | 25.7 | 0.004 |
deterioration | 12 | 12.5 | 7 | 7.3 | 2 | 2.1 | 14 | 14.4 | 0.013 |
Medication for secondary prevention | |||||||||
anticoagulant | 42 | 43.7 | 40 | 41.6 | 34 | 35.4 | 39 | 40.2 | 0.681 |
antiplatelet | 55 | 57.2 | 56 | 58.3 | 53 | 55.2 | 51 | 52.5 | 0.859 |